Michael
Kaseta
Chief Operating Officer & Chief Financial Officer
Michael Kaseta joined Liquidia in 2020 where he serves as Chief Operating Officer and Chief Financial Officer. His extensive background spans corporate finance, business strategy and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Prior to Liquidia, Michael served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, he served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent 11 years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Michael holds a Bachelor of Business Administration in accounting from James Madison University, is a Certified Public Accountant (inactive) licensed in the state of New Jersey and serves on the Board of Directors at Heron Therapeutics and Bryn Pharma.
Michael Kaseta joined Liquidia in 2020 where he serves as Chief Operating Officer and Chief Financial Officer. His extensive background spans corporate finance, business strategy and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Prior to Liquidia, Michael served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, he served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent 11 years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Michael holds a Bachelor of Business Administration in accounting from James Madison University, is a Certified Public Accountant (inactive) licensed in the state of New Jersey and serves on the Board of Directors at Heron Therapeutics and Bryn Pharma.